200 related articles for article (PubMed ID: 38203214)
1. A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients with Metastatic Colorectal Cancer Who Have Failed First-Line Therapy.
Gambaro K; Marques M; McNamara S; Couetoux du Tertre M; Hoffert C; Srivastava A; Schab A; Alcindor T; Langleben A; Sideris L; Abdelsalam M; Tehfe M; Couture F; Batist G; Kavan P
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203214
[TBL] [Abstract][Full Text] [Related]
2. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
3. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Circulating DNA to Assess Prognoses for Metastatic Colorectal Cancer Patients Treated with Regorafenib Dose-Escalation Therapy: A Retrospective, Exploratory Analysis of the RECC Trial.
Ohta R; Yamada T; Nakamura M; Enomoto M; Takahashi M; Yokomizo H; Kosugi C; Ishimaru K; Sonoda H; Kuramochi H; Yoshida Y; Furuya S; Hirata K; Yoshida H; Nozawa K; Hashiguchi Y; Ishida H; Koda K; Katsumata K; Sakamoto K
Digestion; 2023; 104(3):233-242. PubMed ID: 36646047
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.
Petrioli R; Chirra M; Messuti L; Fiaschi AI; Savelli V; Martellucci I; Francini E
Clin Colorectal Cancer; 2018 Dec; 17(4):307-312. PubMed ID: 29548772
[TBL] [Abstract][Full Text] [Related]
6. Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study.
Ducreux M; Petersen LN; Öhler L; Bergamo F; Metges JP; de Groot JW; Wang JY; García Paredes B; Dochy E; Fiala-Buskies S; Cervantes A; O'Connor JM; Falcone A;
Eur J Cancer; 2019 Dec; 123():146-154. PubMed ID: 31698328
[TBL] [Abstract][Full Text] [Related]
7. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
[TBL] [Abstract][Full Text] [Related]
8. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.
Adenis A; de la Fouchardiere C; Paule B; Burtin P; Tougeron D; Wallet J; Dourthe LM; Etienne PL; Mineur L; Clisant S; Phelip JM; Kramar A; Andre T
BMC Cancer; 2016 Jul; 16():412. PubMed ID: 27389564
[TBL] [Abstract][Full Text] [Related]
9. Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients.
Moretto R; Rossini D; Capone I; Boccaccino A; Perrone F; Tamborini E; Masi G; Antoniotti C; Marmorino F; Conca V; Borelli B; Martignetti A; Pecora I; Simionato F; Cupini S; Ambrosini M; Manca P; Pietrantonio F; Falcone A; Cremolini C
Clin Colorectal Cancer; 2021 Dec; 20(4):314-317. PubMed ID: 34364814
[TBL] [Abstract][Full Text] [Related]
10. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.
Van Cutsem E; Martinelli E; Cascinu S; Sobrero A; Banzi M; Seitz JF; Barone C; Ychou M; Peeters M; Brenner B; Hofheinz RD; Maiello E; André T; Spallanzani A; Garcia-Carbonero R; Arriaga YE; Verma U; Grothey A; Kappeler C; Miriyala A; Kalmus J; Falcone A; Zaniboni A
Oncologist; 2019 Feb; 24(2):185-192. PubMed ID: 30190299
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib.
Liu Y; Lyu J; Bell Burdett K; Sibley AB; Hatch AJ; Starr MD; Brady JC; Hammond K; Marmorino F; Rossini D; Goldberg RM; Falcone A; Cremolini C; Owzar K; Ivanova A; Moore DT; Lee MS; Sanoff HK; Innocenti F; Nixon AB
Mol Cancer Ther; 2020 Oct; 19(10):2146-2154. PubMed ID: 32747417
[TBL] [Abstract][Full Text] [Related]
12. Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment.
Pastor B; André T; Henriques J; Trouilloud I; Tournigand C; Jary M; Mazard T; Louvet C; Azan S; Bauer A; Roch B; Sanchez C; Vernerey D; Thierry AR; Adenis A
Mol Oncol; 2021 Sep; 15(9):2401-2411. PubMed ID: 33934494
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Regorafenib in Combination with Chemotherapy as Second-Line Treatment in Patients with Metastatic Colorectal Cancer: A Network Meta-Analysis and Systematic Literature Review.
Xie X; Zhang J; Hu H; Cai Y; Wu Z; Ling J; Li W; Deng Y
Adv Ther; 2020 Oct; 37(10):4233-4248. PubMed ID: 32770529
[TBL] [Abstract][Full Text] [Related]
14. FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer.
Adenis A; Mazard T; Fraisse J; Chalbos P; Pastor B; Evesque L; Ghiringhelli F; Mollevi C; Delaine S; Ychou M
BMC Cancer; 2021 May; 21(1):564. PubMed ID: 34001059
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 Expression on Circulating Tumour Cells May Be Predictive of Response to Regorafenib in Patients Diagnosed with Chemorefractory Metastatic Colorectal Cancer.
Raimondi L; Raimondi FM; Di Benedetto L; Cimino G; Spinelli GP
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962309
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study.
Dane F; Ozgurdal K; Yalçın Ş; Benekli M; Aykan NF; Yücel İ; Özkan M; Evrensel T; Sevinç A; Coskun HŞ; Sanli UA; Kara IO; Yumuk PF
BMJ Open; 2020 Mar; 10(3):e027665. PubMed ID: 32220908
[TBL] [Abstract][Full Text] [Related]
17. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.
Lee JJ; Chu E
Clin Colorectal Cancer; 2014 Sep; 13(3):135-44. PubMed ID: 24768040
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
Lu X; Li Y; Li Y; Zhang X; Shi J; Feng H; Yu Z; Gao Y
BMC Cancer; 2023 Nov; 23(1):1117. PubMed ID: 37974093
[TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
Fogelman D; Cubillo A; García-Alfonso P; Mirón MLL; Nemunaitis J; Flora D; Borg C; Mineur L; Vieitez JM; Cohn A; Saylors G; Assad A; Switzky J; Zhou L; Bendell J
Cancer Med; 2018 Nov; 7(11):5382-5393. PubMed ID: 30123970
[TBL] [Abstract][Full Text] [Related]
20. Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study.
Cardone C; De Stefano A; Rosati G; Cassata A; Silvestro L; Borrelli M; Di Gennaro E; Romano C; Nappi A; Zanaletti N; Foschini F; Casaretti R; Tatangelo F; Lastoria S; Raddi M; Bilancia D; Granata V; Setola S; Petrillo A; Vitagliano C; Gargiulo P; Arenare L; Febbraro A; Martinelli E; Ciardiello F; Delrio P; Budillon A; Piccirillo MC; Avallone A
ESMO Open; 2023 Feb; 8(1):100748. PubMed ID: 36603521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
